What Dextrose 35% Vioser Treats: Main Uses and Benefits

Dextrose 35% Vioser is commonly used as a source of energy support for patients requiring parenteral nutritional support. The solution is relevant in clinical settings for patients requiring complete intravenous support. It serves to address the profound symptomatic burden of caloric deficit and severe malnutrition, providing an immediate, concentrated source of energy to sustain vital organ function and stability. It may assist with supportive management for patients experiencing severe malnutrition, prolonged fasting states, or acute metabolic stress.

It is used to address symptoms related to systemic imbalance, such as the confusion and distress associated with severe hypoglycemia, and provides supportive management during hypercatabolic states following major trauma or sepsis. A key benefit is its supportive role in managing symptoms related to systemic imbalance and contributing to stability during periods of heightened metabolic stress. It may assist with supportive management during temporary physiological imbalance related to severe fluid and nutrient depletion.

“The introduction of concentrated glucose contributes to a sense of stability when symptoms are more noticeable, especially for patients with significantly elevated energy demands.”

Quick Fact: Supportive Management for Metabolic Symptoms
Primary Therapeutic Use	Component of Total Parenteral Nutrition (TPN).
Symptom Management Focus	Severe Hypoglycemia and symptoms related to carbohydrate depletion.
Key Benefit	Supports the body during periods of high physiological stress.

Dextrose 35% Vioser is intended for patients requiring parenteral nutritional support and must be used according to specific regulatory eligibility rules, which focus on metabolic and fluid stability.

Absolute Contraindications

The solution is contraindicated and must not be used in patients with clinically significant hyperglycemia or known hypersensitivity to dextrose or corn products. Absolute non-eligibility also applies to patients with anuria, severe dehydration, or those presenting with intracranial or intraspinal haemorrhage.

Conditional Eligibility and Restrictions

Use is conditional and requires specific caution in several populations. Patients with pre-existing impaired glucose tolerance or diabetes mellitus must be closely monitored due to the risk of exacerbating hyperglycemia. Similarly, patients with renal impairment or risk factors for hyponatremia require restricted use. In cases of severe malnutrition, caution is mandatory due to the regulatory-documented risk of precipitating Refeeding Syndrome.

Age-Related Eligibility

The hypertonic solution is not recommended for routine infusion in neonates and low birth weight infants. Geriatric patients and pediatric patients require careful dosing due to specific risks associated with fluid shifts and decreased organ function. Use during pregnancy is allowed only if clearly needed, as safety is not formally established, and caution is advised during lactation.

Dextrose 35% Vioser Interactions with other medicines and products

Official regulatory information for Dextrose 35% Vioser focuses on managing pharmacodynamic effects related to systemic balance and procedural constraints based on physical incompatibilities. No specific medicinal product combination is formally listed as a contraindicated interaction.

Documented Pharmacodynamic Interactions

Interactions are primarily noted with medicines that alter the body’s internal balance. The official label advises caution when co-administering:

• Corticosteroids and Corticotropin: These agents may reduce glucose uptake and increase fluid retention, potentially aggravating hyperglycemia or electrolyte imbalances caused by the Dextrose solution.
• Medicinal Products Affecting Glycemic or Fluid Balance: The metabolic effects of Dextrose must be considered when used alongside any other drugs that influence blood glucose levels or fluid/electrolyte homeostasis.

Procedural and Population-Specific Constraints

Constraint Type	Interacting Product / Population	Restriction Based on Regulatory Information
Physical Incompatibility	Blood Products	Must not be administered simultaneously through the same IV line due to the risk of pseudoagglutination or hemolysis.
Increased Risk of Hyponatremia	Drugs Increasing Vasopressin Effect (e.g., NSAIDs, SSRIs, Oxytocin)	Increases the risk of severe hyponatremia and encephalopathy, particularly in vulnerable groups like pediatric and geriatric patients.
General Caution	Geriatric Patients	Caution is advised due to the higher likelihood of concomitant drug therapy and reduced renal or hepatic function.

These constraints establish the structure of the solution’s interaction profile by emphasizing required co-administration rules and risk mitigation.

Dextrose, the aldohexose stereoisomer D-glucose, is a monosaccharide introduced into the systemic circulation. Following intravenous administration, the 35% concentration solution generates a high solute load, modulating the plasma osmolarity and driving the systemic distribution of glucose to cellular compartments. Glucose traverses the cell membrane primarily via facilitated diffusion mediated by various glucose transporter (GLUT) proteins, which are differentially expressed across tissues.

Once intracellular, the glucose substrate is phosphorylated by hexokinase to generate glucose-6-phosphate, initiating the molecular pathway of glycolysis. This initial step commits the substrate to catabolism. The subsequent enzymatic reactions of the glycolytic pathway convert the six-carbon molecule into two molecules of pyruvate, generating a net gain of adenosine triphosphate (ATP) via substrate-level phosphorylation and reducing equivalents (NADH). Pyruvate enters the mitochondrial matrix, where it is further oxidized via the tricarboxylic acid (TCA) cycle and subsequent oxidative phosphorylation. This process yields a substantially greater quantity of ATP, establishing the system-level physiological consequence of supplying a primary and readily available metabolic energy source for various organ systems, including the obligate glucose consumer, the central nervous system.

Dextrose 35% Vioser is a high-concentration sterile solution that must be administered only via Intravenous Infusion. Due to its high osmolarity, this solution is delivered into a central vein to ensure rapid dilution and prevent local venous irritation and damage.

Official Administration Guidelines

Preparation Requirements

The 35% concentration is not intended for direct intravenous use. Instead, it must be diluted with compatible intravenous fluids or used as a concentrated admixture component for Total Parenteral Nutrition (TPN) with amino acids and other required nutrients.

Dosing and Rate

The dose is highly individualized based on the patient's caloric requirements, fluid status, and metabolic condition. The administration is typically a continuous infusion over a prolonged period. A core principle of use is adherence to a maximum infusion rate, which is commonly cited as 0.5 g of glucose per kg body weight per hour to prevent excessive glucose levels and glycosuria. The daily intake is usually increased gradually at the beginning of therapy to allow metabolic adaptation.

Procedural Constraints

Administration must be separated from blood products; the solution should not be administered simultaneously with blood through the same infusion set. When discontinuing the therapy, the infusion rate must be slowly tapered off over a period of 30 to 60 minutes to prevent the metabolic event of rebound hypoglycemia. For sensitive populations, such as neonates and older adults, the initial dosing must begin at the lowest practical rate due to increased risks of glucose and fluid imbalance.

Research Evidence / Overview of Studies for Dextrose 35% Vioser

---

Evidence for Managing Low Blood Sugar (Hypoglycemia)

Research has primarily focused on the use of concentrated glucose solutions like Dextrose 35% Vioser, exploring how to respond to a temporary physiological imbalance caused by severe low blood sugar. These studies, often conducted in acute care settings, monitored the immediate effect on blood sugar levels over defined time intervals following administration. The findings describe patterns where this type of glucose solution was associated with an increase in blood sugar, which contributes to the broader evidence landscape for managing emergency low blood sugar.

However, the evidence is limited regarding the long-term impact of repeated use, and comparative evidence is lacking regarding potential differences compared to other glucose solutions. Research is still ongoing in this area.

---

Evidence for Use in Nutritional Support (Total Parenteral Nutrition)

Dextrose 35% Vioser was evaluated in studies as a necessary component of intravenous feeding (Total Parenteral Nutrition, or TPN) for patients whose study protocols included not receiving nutrition by mouth. The studies examined the solution's effect on outcomes related to systemic or functional imbalance, such as energy intake and general metabolic parameters in a hospital setting. The data show patterns related to how the solution, used as part of a complete TPN mixture, was evaluated for its role in glucose intake for energy.

Limitations exist because overall outcomes are tied to the entire TPN formulation. Evidence quality varies across studies, and results apply only to the populations studied. Researchers are still exploring optimal formulations for TPN in various patient groups.

---

Long-term Studies and Follow-up

Research explores the question of long-term outcomes following treatment. Long-term effects are not fully established for either primary use. Follow-up durations were limited in many key studies, meaning there is limited information for understanding the durability of the effect or any extended-duration patterns. Research provides context but not individual predictions.

---

Evidence in Special Populations

The use of Dextrose 35% Vioser was studied for various groups, including children, particularly when they were studied during acute episodes, and older adults. However, the sample sizes were modest in many of these studies. Data for certain groups remain insufficient, and certainty remains low for definitive conclusions. Subgroup findings are uncertain, and research does not determine whether an individual will respond similarly.

---

What is Still Uncertain about Dextrose 35% Vioser

Research highlights several areas where knowledge is incomplete. Findings were mixed or inconsistent in some trials. The main areas of uncertainty relate to the fact that long-term effects are not fully established, and comparative evidence is lacking. The research contributes to understanding short-term changes, but ongoing studies will need to address these evidence gaps.

Key Studies & References

1. The Use of Parenteral Nutrition in Neonatal and Paediatric Units - National Clinical Practice Guideline (Used for TPN and Special Populations - Pediatric context)
2. ESPEN practical guideline: Home parenteral nutrition (Used for TPN context and long-term uncertainty framing)

Common questions about Dextrose 35% Vioser (FAQ)

Q: What is Dextrose 35% Vioser used for?

Dextrose 35% Vioser is a hypertonic glucose solution (meaning it has a high concentration of sugar) administered intravenously. Official product information states it is primarily used to provide energy (calories) in a concentrated form, particularly when other methods of nutrition are not suitable. It is also used to treat low blood sugar (hypoglycemia) and as a carbohydrate source during periods of illness or malnutrition.

Q: What is Dextrose 35% Vioser made of?

The regulatory documents indicate that the main active ingredient is Dextrose (glucose) at a concentration of 35 grams per 100 mL of solution. This high concentration is what makes it a hypertonic solution. The product also contains water for injection and may include other components to adjust the solution's pH level.

Q: How is Dextrose 35% Vioser administered?

Dextrose 35% Vioser is designed to be administered through a slow, continuous infusion directly into a vein. According to official guidelines, it is generally infused through a central vein, rather than a smaller peripheral vein, due to its high concentration (hypertonicity). The administration is performed by a healthcare professional.

Q: Are there any specific safety checks needed before receiving Dextrose 35% Vioser?

Official product information highlights that several safety checks are typically performed before starting treatment. These checks include assessing the patient's fluid balance, electrolyte levels (like potassium and phosphate), and blood sugar levels (glycemia). The prescribing physician reviews the patient's medical history to identify any underlying conditions that might affect the use of this product, based on official information.

Q: What should be monitored while receiving Dextrose 35% Vioser?

Due to its effects on the body’s chemistry, official sources recommend careful monitoring during infusion. This includes frequent checks of blood sugar levels (glycemia) to prevent both high and low blood sugar, as well as regular monitoring of water balance, kidney function, and electrolyte levels (such as potassium, magnesium, and phosphate) to ensure stability.

How to Store and Dispose of Dextrose 35% Vioser?

Dextrose 35% Vioser must be stored and handled according to specific regulatory requirements to maintain its stability and sterility. The unopened product must be stored at or below 25 C (77 F) and must not freeze. It should be kept in its original overwrap until immediately before use and checked for container damage or leaks.

Stability and Handling

This is a single-use container. Once the closure is punctured, the contents must be withdrawn promptly, or the container must be discarded no later than 4 hours after the initial entry to ensure sterility. Keep out of reach of children.

Disposal

Any unused portion of the product and the container must be discarded after use. Disposal must be conducted in accordance with local requirements for pharmaceutical waste.